A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren ’s syndrome patients
DiscussionThis is the first randomized controlled study to evaluate the clinical efficacy and safety of baricitinib in pSS. We hope that the result of this study can provide more reliable evidence of the efficacy and safety of baricitinib in pSS.Trial registrationClinicalTrials.gov NCT05016297. Registered on 19 Aug 2021. (Source: Trials)
Source: Trials - February 15, 2023 Category: Research Source Type: clinical trials

Evaluation of Hydroxychloroquine to Prevent CIPN
Conditions:   Breast Cancer;   Gynecologic Cancer;   Early-stage Breast Cancer;   Peripheral Neuropathy;   Chemotherapy-induced Peripheral Neuropathy Intervention:   Drug: Hydroxychloroquine Sponsor:   University of Arizona Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2023 Category: Research Source Type: clinical trials

Tacrolimus for Thrombocytopenia in SS
Condition:   Sjogren Syndrome With Other Organ Involvement Interventions:   Drug: Hydroxychloroquine;   Drug: Tacrolimus Sponsor:   Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 10, 2023 Category: Research Source Type: clinical trials